149 related articles for article (PubMed ID: 10945631)
1. Activation of CPT-11 in mice: identification and analysis of a highly effective plasma esterase.
Morton CL; Wierdl M; Oliver L; Ma MK; Danks MK; Stewart CF; Eiseman JL; Potter PM
Cancer Res; 2000 Aug; 60(15):4206-10. PubMed ID: 10945631
[TBL] [Abstract][Full Text] [Related]
2. Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice.
Morton CL; Iacono L; Hyatt JL; Taylor KR; Cheshire PJ; Houghton PJ; Danks MK; Stewart CF; Potter PM
Cancer Chemother Pharmacol; 2005 Dec; 56(6):629-36. PubMed ID: 15918039
[TBL] [Abstract][Full Text] [Related]
3. Metabolism of CPT-11. Impact on activity.
Rivory LP
Ann N Y Acad Sci; 2000; 922():205-15. PubMed ID: 11193896
[TBL] [Abstract][Full Text] [Related]
4. Proficient metabolism of irinotecan by a human intestinal carboxylesterase.
Khanna R; Morton CL; Danks MK; Potter PM
Cancer Res; 2000 Sep; 60(17):4725-8. PubMed ID: 10987276
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials.
Rivory LP; Haaz MC; Canal P; Lokiec F; Armand JP; Robert J
Clin Cancer Res; 1997 Aug; 3(8):1261-6. PubMed ID: 9815808
[TBL] [Abstract][Full Text] [Related]
6. Structural constraints affect the metabolism of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) by carboxylesterases.
Wadkins RM; Morton CL; Weeks JK; Oliver L; Wierdl M; Danks MK; Potter PM
Mol Pharmacol; 2001 Aug; 60(2):355-62. PubMed ID: 11455023
[TBL] [Abstract][Full Text] [Related]
7. Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies.
Kehrer DF; Yamamoto W; Verweij J; de Jonge MJ; de Bruijn P; Sparreboom A
Clin Cancer Res; 2000 Sep; 6(9):3451-8. PubMed ID: 10999728
[TBL] [Abstract][Full Text] [Related]
8. Nonlinear pharmacokinetics of CPT-11 in rats.
Kaneda N; Yokokura T
Cancer Res; 1990 Mar; 50(6):1721-5. PubMed ID: 2306726
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic characteristics of the novel anticancer agent CPT-11 and its active metabolite in plasma and lung lymph fluid following intravenous administration to sheep.
Koizumi T; Kubo K; Hanaoka M; Miyahara T; Kaneki T; Yamamoto H; Ge RL; Fujimoto K; Kobayashi T; Sekiguchi M
Arzneimittelforschung; 1998 Nov; 48(11):1097-100. PubMed ID: 9850432
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of prolonged-release CPT-11-loaded microspheres in rats.
Machida Y; Onishi H; Kurita A; Hata H; Morikawa A; Machida Y
J Control Release; 2000 May; 66(2-3):159-75. PubMed ID: 10742577
[TBL] [Abstract][Full Text] [Related]
11. Modulation of irinotecan metabolism by ketoconazole.
Kehrer DF; Mathijssen RH; Verweij J; de Bruijn P; Sparreboom A
J Clin Oncol; 2002 Jul; 20(14):3122-9. PubMed ID: 12118026
[TBL] [Abstract][Full Text] [Related]
12. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse.
Kaneda N; Nagata H; Furuta T; Yokokura T
Cancer Res; 1990 Mar; 50(6):1715-20. PubMed ID: 2306725
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of orally administered camptothecins.
Gupta E; Vyas V; Ahmed F; Sinko P; Cook T; Rubin E
Ann N Y Acad Sci; 2000; 922():195-204. PubMed ID: 11193895
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of CPT-11 in rhesus monkeys.
Inaba M; Ohnishi Y; Ishii H; Tanioka Y; Yoshida Y; Sudoh K; Hakusui H; Mizuno N; Ito K; Sugiyama Y
Cancer Chemother Pharmacol; 1998; 41(2):103-8. PubMed ID: 9443622
[TBL] [Abstract][Full Text] [Related]
15. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients.
Rivory LP; Chatelut E; Canal P; Mathieu-Boué A; Robert J
Cancer Res; 1994 Dec; 54(24):6330-3. PubMed ID: 7987823
[TBL] [Abstract][Full Text] [Related]
16. The crystal structure of the complex of the anticancer prodrug 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) with Torpedo californica acetylcholinesterase provides a molecular explanation for its cholinergic action.
Harel M; Hyatt JL; Brumshtein B; Morton CL; Yoon KJ; Wadkins RM; Silman I; Sussman JL; Potter PM
Mol Pharmacol; 2005 Jun; 67(6):1874-81. PubMed ID: 15772291
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11.
Sasaki Y; Yoshida Y; Sudoh K; Hakusui H; Fujii H; Ohtsu T; Wakita H; Igarashi T; Itoh K
Jpn J Cancer Res; 1995 Jan; 86(1):111-6. PubMed ID: 7737902
[TBL] [Abstract][Full Text] [Related]
18. Haplotypes and a novel defective allele of CES2 found in a Japanese population.
Kim SR; Sai K; Tanaka-Kagawa T; Jinno H; Ozawa S; Kaniwa N; Saito Y; Akasawa A; Matsumoto K; Saito H; Kamatani N; Shirao K; Yamamoto N; Yoshida T; Minami H; Ohtsu A; Saijo N; Sawada J
Drug Metab Dispos; 2007 Oct; 35(10):1865-72. PubMed ID: 17640957
[TBL] [Abstract][Full Text] [Related]
19. The importance of tumor glucuronidase in the activation of irinotecan in a mouse xenograft model.
Dodds HM; Tobin PJ; Stewart CF; Cheshire P; Hanna S; Houghton P; Rivory LP
J Pharmacol Exp Ther; 2002 Nov; 303(2):649-55. PubMed ID: 12388647
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
Rowinsky EK; Grochow LB; Ettinger DS; Sartorius SE; Lubejko BG; Chen TL; Rock MK; Donehower RC
Cancer Res; 1994 Jan; 54(2):427-36. PubMed ID: 8275479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]